CM 2489

Drug Profile

CM 2489

Alternative Names: CCI; CM-2489; CRAC channel inhibitor - CalciMedica

Latest Information Update: 17 Nov 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator CalciMedica
  • Class Antipsoriatics; Small molecules
  • Mechanism of Action Immunosuppressants; ORAI1 protein inhibitors; STIM1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Plaque psoriasis

Most Recent Events

  • 17 Nov 2016 Discontinued - Phase-I for Plaque psoriasis in USA (PO) before November 2016 (CalciMedica's website, November 2016)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Plaque-psoriasis in USA (PO)
  • 17 Feb 2011 Phase-I clinical trials in Plaque psoriasis (in volunteers) in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top